StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Equities research analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on shares of InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target for the company.

InspireMD Stock Performance

Shares of NYSE NSPR opened at $2.76 on Thursday. The stock has a market cap of $71.98 million, a PE ratio of -3.68 and a beta of 1.00. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42. The stock has a fifty day moving average of $2.80 and a 200-day moving average of $2.74.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same quarter in the previous year, the firm earned ($0.15) EPS. On average, sell-side analysts predict that InspireMD will post -0.79 EPS for the current year.

Institutional Trading of InspireMD

A number of institutional investors have recently made changes to their positions in NSPR. Affiance Financial LLC raised its stake in InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after buying an additional 5,376 shares in the last quarter. Legato Capital Management LLC purchased a new position in InspireMD during the fourth quarter valued at $47,000. Essex Investment Management Co. LLC purchased a new position in InspireMD during the fourth quarter valued at $191,000. Finally, Parkman Healthcare Partners LLC purchased a new position in InspireMD during the third quarter valued at $279,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.